TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
CAMBRIDGE, Mass., Oct. 31, 2016 -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Monday, November 7, 2016, at 5:00 p.m. ET to discuss a corporate update and results for the third quarter of 2016.
To access the call, please dial 877-809-6321 (domestic) or 615-247-0223 (international) and provide the passcode 8708082. A live webcast of the presentation will be available on the Investors & Media section of the Editas website at www.editasmedicine.com.
About Editas Medicine
Editas Medicine is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting their disease-causing genes. The Company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.
Media Contact Dan Budwick Pure Communications, Inc. (973) 271-6085 [email protected] Investor Contact Mark Mullikin Editas Medicine, Inc. (617) 401-9083 [email protected]
